Would recurrent urolithiasis, nephrocalcinosis or unexplained end-stage kidney disease (ESKD) make you think of primary hyperoxaluria type 1 (PH1)?
Recognising the signs is the first step in managing this progressive disease.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Developed by EPG Health for Medthority.com, with all content provided by Alnylam Pharmaceuticals. Learning Zone sponsored and funded by Alnylam Pharmaceuticals. Please note that this material is intended for healthcare professionals only.
Date of preparation: March 2021 │ OXL-CEMEA-00010
© Copyright 2021